ABUS Arbutus Biopharma Corp

Price (delayed)

$4.29

Market cap

$847.44M

P/E Ratio

5.11

Dividend/share

N/A

EPS

$0.84

Enterprise value

$827.64M

?
Relative Growth: Rel. Growth: 91
Relative Strength: Rel. Strength: 51
Relative Valuation: Rel. Valuation: 95
Relative Profitability: Rel. Profitability: 100

Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple ...

Highlights
The debt has declined by 30% year-on-year and by 7% since the previous quarter
ABUS's quick ratio is up by 22% QoQ

Key stats

What are the main financial stats of ABUS

ABUS stock price

How has the Arbutus Biopharma stock price performed over time
Intraday
-1.38%
1 week
-6.74%
1 month
-2.28%
1 year
25.81%
YTD
-10.81%
QTD
-4.67%

Financial performance

How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$191.45M
Gross profit
$191.45M
Operating income
$154.53M
Net income
$160.72M
Gross margin
100%
Net margin
84%
The net margin has surged by 135% since the previous quarter and by 107% year-on-year
ABUS's operating margin has surged by 128% since the previous quarter and by 106% year-on-year

Price vs fundamentals

How does ABUS's price correlate with its fundamentals

Growth

What is Arbutus Biopharma's growth rate over time

Valuation

What is Arbutus Biopharma stock price valuation
P/E
5.11
P/B
3.22
P/S
4.34
EV/EBIT
5.15
EV/EBITDA
5.15
EV/Sales
4.32
ABUS's price to book (P/B) is 62% lower than its last 4 quarters average of 8.5 and 32% lower than its 5-year quarterly average of 4.8
The price to sales (P/S) is 90% lower than the last 4 quarters average of 42.0 and 89% lower than the 5-year quarterly average of 40.3

Efficiency

How efficient is Arbutus Biopharma business performance
The company's return on sales has surged by 135% QoQ and by 107% YoY

Dividends

What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABUS.

Financial health

How did Arbutus Biopharma financials performed over time
The company's total assets has surged by 193% QoQ and by 137% YoY
ABUS's total liabilities has dropped by 55% year-on-year and by 6% since the previous quarter
The debt is 98% smaller than the equity
ABUS's debt to equity has dropped by 71% year-on-year and by 60% since the previous quarter
The debt has declined by 30% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.